UMB Bank n.a. trimmed its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 19.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 860 shares of the company’s stock after selling 213 shares during the quarter. UMB Bank n.a.’s holdings in Sanofi were worth $41,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Clarius Group LLC raised its position in Sanofi by 11.9% during the 4th quarter. Clarius Group LLC now owns 4,708 shares of the company’s stock worth $227,000 after purchasing an additional 500 shares during the last quarter. HF Advisory Group LLC lifted its stake in shares of Sanofi by 7.1% in the fourth quarter. HF Advisory Group LLC now owns 30,812 shares of the company’s stock worth $1,486,000 after acquiring an additional 2,049 shares during the period. Aaron Wealth Advisors LLC boosted its holdings in Sanofi by 7.5% in the fourth quarter. Aaron Wealth Advisors LLC now owns 23,904 shares of the company’s stock valued at $1,153,000 after acquiring an additional 1,665 shares during the last quarter. HB Wealth Management LLC increased its position in Sanofi by 151.8% during the 4th quarter. HB Wealth Management LLC now owns 15,496 shares of the company’s stock valued at $747,000 after purchasing an additional 9,342 shares during the period. Finally, Financial & Tax Architects LLC lifted its position in shares of Sanofi by 14.8% in the 4th quarter. Financial & Tax Architects LLC now owns 11,824 shares of the company’s stock worth $570,000 after purchasing an additional 1,525 shares during the period. 14.04% of the stock is currently owned by institutional investors.
Sanofi Stock Performance
NASDAQ:SNY opened at $52.48 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a fifty day moving average of $48.70 and a 200-day moving average of $52.19. The firm has a market capitalization of $133.19 billion, a P/E ratio of 26.78, a P/E/G ratio of 1.19 and a beta of 0.57.
Analyst Ratings Changes
Separately, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.
Read Our Latest Stock Analysis on SNY
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
- Five stocks we like better than Sanofi
- What Are Some of the Best Large-Cap Stocks to Buy?
- Bloom Energy: Powering the Future With Decentralized Energy
- How to Choose Top Rated Stocks
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- How to Start Investing in Real Estate
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.